Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02482025 · ClinicalTrials.gov registry record · NA

The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial

A NA study of Adverse Drug Events and Drug-Related Side Effects and Adverse Reactions, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
240
Enrollment target
1
Study location

NCT02482025: Completed NA study of Adverse Drug Events and Drug-Related Side Effects and Adverse Reactions, sponsored by VA Office of Research and Development.

NCT02482025 is a NA study of Adverse Drug Events and Drug-Related Side Effects and Adverse Reactions that has completed, run by VA Office of Research and Development. The registered enrollment target is 240 participants, below the 749-participant average among 6 other Adverse Drug Events trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02482025, a NA study of Adverse Drug Events and Drug-Related Side Effects and Adverse Reactions, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
240 participants
Enrollment target
1
Study location

Study Summary

Medication discrepancies, defined as unintentional differences found between patients' medical records and patients' reports of the medication they are taking, occur frequently after hospital discharge, predisposing to adverse drug events (ADEs), emergency department visits and readmissions. Resolving medication discrepancies - medication reconciliation - is mandated at every care transition, but little is known about intervention strategies to improve medication reconciliation in the post-discharge period, when patients may lack prompt access to primary care and are at high risk for ADEs. To address this gap, the investigators developed and pilot tested the Secure Messaging for Medication Reconciliation Tool (SMMRT), with a pharmacist communicating with Veterans to review medications and reconcile discrepancies after hospital discharge via Secure Messaging (SM), within My HealtheVet (MHV), VA's patient portal. The objectives of The SMMRT Trial are therefore To optimize the end-users' experience with SMMRT through usability testing and refinement of the tool; To conduct a randomized controlled trial (RCT) of usual care vs. usual care plus MHV Training vs. usual care plus MHV Training plus SMMRT to reduce hospital utilization; To evaluate how Veterans and staff perceived the impact of SMMRT on routine clinical practices and, specifically, on Veterans' interactions with their primary care providers.

Primary Outcome

Medication discrepancies (discrepancies between what the patient is taking and what is in the medical record) identified 30 days after hospitalization via telephone interview and review of medical record

Interventions

  • OTHER SMMRT

Study Locations (1)

Massachusetts

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA - Boston

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2018-11-16
Est. Completion 2020-06-10
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT02482025 record still lists

NCT02482025 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, below the 749-participant average among 6 other Adverse Drug Events trials with a reported enrollment target (68% lower).

The record links to 2 conditions, with Adverse Drug Events appearing as the primary indexed condition, and to 1 intervention - of which SMMRT is the first listed.

NCT02482025 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02482025 about?

NCT02482025 is a clinical study titled "The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial". Medication discrepancies, defined as unintentional differences found between patients' medical records and patients' reports of the medication they are taking, occur frequently after hospital discharge, predisposing to adverse drug events (ADEs), emergency department visits and readmissions. Resolvi...

What is the current status of trial NCT02482025?

This trial is currently completed. It is a NA study. The enrollment target is 240 participants. The study started on 2018-11-16. Estimated completion is 2020-06-10.

What conditions does trial NCT02482025 study?

This clinical trial studies the following conditions: Adverse Drug Events, Drug-Related Side Effects and Adverse Reactions.

What interventions are being tested in trial NCT02482025?

The interventions under investigation include: SMMRT (OTHER).

Who is sponsoring clinical trial NCT02482025?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02482025 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Adverse Drug Events

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02855554 · 240 participants · NA

    Quantitative Cardiac Parametric Mapping

  • NCT03230565 · 240 participants · Phase 4

    Continuous Infusions vs Scheduled Bolus Infusions

  • NCT03399929 · 240 participants

    Traumatic Brain Injury and Stroke Long Term Outcome

  • NCT03583710 · 240 participants · Phase 3

    Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02482025, the US trial registry maintained by the National Library of Medicine. NCT02482025 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.